Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
4
USD
|
+4.99%
|
|
+5.96%
|
-45.91%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
194.9
|
227.5
|
123
|
34.12
|
15.47
|
8.378
|
-
|
-
|
Enterprise Value (EV)
1 |
194.9
|
106.2
|
123
|
34.12
|
15.47
|
8.378
|
8.378
|
8.378
|
P/E ratio
|
-7.14
x
|
-3.96
x
|
-2.44
x
|
-0.87
x
|
-0.44
x
|
-0.31
x
|
-0.31
x
|
-0.29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
11.2
x
|
3.72
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
11.2
x
|
3.72
x
|
EV / EBITDA
|
-
|
-
|
-2,091,834
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-7,400,189
x
|
-4,112,476
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,278
|
2,027
|
2,067
|
2,068
|
2,092
|
2,094
|
-
|
-
|
Reference price
2 |
152.5
|
112.2
|
59.50
|
16.50
|
7.395
|
4.000
|
4.000
|
4.000
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.75
|
2.25
|
EBITDA
|
-
|
-
|
-58.8
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-34.55
|
-50.95
|
-59.98
|
-48.88
|
-41.69
|
-34.94
|
-36.87
|
-40.69
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,915.76%
|
-1,808.33%
|
Earnings before Tax (EBT)
1 |
-33.19
|
-50.6
|
-59.85
|
-48.04
|
-40.73
|
-34.88
|
-36.9
|
-40.73
|
Net income
1 |
-27.7
|
-42.92
|
-50.75
|
-40
|
-35.14
|
-30.55
|
-32.67
|
-36.01
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-4,356.65%
|
-1,600.58%
|
EPS
2 |
-21.35
|
-28.33
|
-24.41
|
-19.05
|
-16.85
|
-12.84
|
-12.70
|
-13.82
|
Free Cash Flow
|
-
|
-30.75
|
-29.91
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.44
|
-19.7
|
-13.14
|
-6.285
|
-7.354
|
-21.55
|
-11.41
|
-8.004
|
-10.25
|
-11.58
|
-8.7
|
-8.767
|
-8.579
|
-8.647
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.41
|
-19.68
|
-13.1
|
-6.126
|
-7.097
|
-21.19
|
-11.06
|
-7.777
|
-10.06
|
-11.41
|
-8.626
|
-8.675
|
-8.5
|
-8.581
|
-
|
Net income
1 |
-10.83
|
-17.08
|
-10.55
|
-4.688
|
-5.38
|
-18.99
|
-9.816
|
-6.903
|
-8.315
|
-9.734
|
-7.479
|
-7.778
|
-7.607
|
-7.437
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-5.052
|
-8.138
|
-5.020
|
-2.108
|
-2.674
|
-9.058
|
-4.679
|
-3.188
|
-4.036
|
-4.450
|
-3.500
|
-3.644
|
-2.812
|
-2.812
|
-4.125
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/18/21
|
4/27/22
|
6/2/22
|
8/17/22
|
11/16/22
|
4/4/23
|
5/17/23
|
8/16/23
|
11/16/23
|
3/20/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
121
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-30.7
|
-29.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-49.2%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.5
|
0.08
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
4/27/22
|
4/4/23
|
3/20/24
|
-
|
-
|
-
|
Average target price
119.8
USD Spread / Average Target +2,895.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -45.91% | 8.38M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|